Systemic lupus erythematosus and the type I interferon system.

Area of Science:

• Immunology
• Molecular Biology
• Autoimmune Diseases

Background:

• Systemic lupus erythematosus (SLE) is characterized by elevated interferon-alpha (IFN-alpha) levels, correlating with disease activity and severity.
• Endogenous inducers, specifically small immune complexes (ICs) containing IgG and DNA, have been identified in SLE patients.
• These ICs target natural IFN-alpha-producing cells (NIPCs), also known as plasmacytoid dendritic cells (PDCs).

Purpose of the Study:

• To review the biology of the type I interferon system, focusing on inducers, producing cells (NIPCs/PDCs), and IFN-alpha actions relevant to SLE.
• To propose a hypothesis on the activation of NIPCs/PDCs and their role in SLE etiopathogenesis.
• To identify potential new therapeutic targets for SLE based on the proposed mechanism.

Main Methods:

• Literature review of the type I interferon system and SLE pathogenesis.
• Analysis of existing studies on IFN-alpha inducers and NIPC/PDC activation in SLE patients.
• Formulation of a hypothesis integrating these findings.

Main Results:

• NIPCs/PDCs play a crucial role in both innate and adaptive immunity.
• IFN-alpha exerts significant immunoregulatory effects.
• Small IgG-DNA immune complexes are identified as specific activators of NIPCs/PDCs in SLE.

Conclusions:

• NIPCs/PDCs are activated by endogenous immune complexes in SLE patients.
• This activation contributes significantly to the etiopathogenesis of SLE.
• Targeting NIPC/PDC activation presents a promising therapeutic strategy for SLE.